Award-Winning Workplace Uses Complex Algorithms to Create Personalized Company Yearbooks for Every Employee
Klick Inc., a six-time-and-counting 2019 Best Workplace award recipient, is rewriting the book on employee engagement.
Celgene Receives European Commission Approvals for Revlimid and Imnovid-Based Triplet Combination Regimens for Multiple Myeloma
Celgene Corporation announced that the European Commission approved two new triplet regimens based on the company’s proprietary IMiD treatments, Revlimid (lenalidomide) and Imnovid (pomalidomide).
Gilead Sciences to Provide Free Truvada for PrEP to Support U.S. Initiative to End HIV Epidemic
Gilead Sciences Inc. announced that the company will donate Truvada for PrEP (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.S. CDC.
Gilead and Goldfinch Bio Form Strategic Collaboration
Gilead Sciences Inc. and Goldfinch Bio Inc. announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.
White Paper: Safety Profile of the Analgesic Trezix™ Capsules, Containing the Mild Opioid Dihydrocodeine
Privately held pharmaceutical company Wraser Pharmaceuticals announced the publication of a White Paper addressing opioid safety.
AACE Meeting: New Data from Phase 3 OPTIC Study
Horizon Pharma announced that new data from the Phase 3 confirmatory study evaluating teprotumumab for treating active thyroid eye disease were presented as part of a late-breaking oral presentation at the 2019 AACE Scientific and Clinical Congress.
Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management
Gelesis announced that the United States Food and Drug Administration cleared the biotechnology company’s lead product candidate Plenity (Gelesis100) as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.
FDA Approves Expanded Label for Keytruda
The U.S. FDA approved an expanded label for Merck’s anti-PD-1 therapy Keytruda as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
U.S. FDA approves ViiV Healthcare’s Dovato
The FDA approved ViiV’s Dovato as a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for treating HIV-1 infection in adults with no antiretroviral treatment history and no known resistance to either DTG or 3TC.
U.S. FDA Approves Ibrance for Treatment of Men with HR+, HER2- Metastatic Breast Cancer
Pfizer announced that the U.S. Food and Drug Administration approved a supplemental New Drug Application to expand the indications for Ibrance (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
Ad Right Top
Most Commented
Sorry. No data so far.
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!